2024 Rachmiel Levine-Arthur Riggs Diabetes Research Symposium

Pasadena, CA US
September 21, 2024 to September 24, 2024

2024 Rachmiel Levine-Arthur Riggs Diabetes Research Symposium

Overview

Despite the significant knowledge obtained and progress made in the treatment of diabetes over the last 100 years since the discovery of insulin, translation of this understanding to the clinic, and implementation of acceptable standards of care for diabetics has been suboptimal and continually evolving. In view of the rapidly growing worldwide diabetes epidemic the disease affects 34.2 million people in the USA and 463 million people worldwide, with projected increase to 700 million worldwide, and one in three Americans by 2045 and beyond. It is imperative to enhance current interactions among investigators, foster new collaborations, pool knowledge and resources so that the cellular and molecular mechanisms responsible for the disease and its associated complications can be determined, as well as develop novel therapeutic strategies that will effectively prevent, delay, and even cure diabetes. Additionally, this meeting will attempt to clarify the interface of cancer and diabetes.

For over 20 years, the Levine-Riggs Symposium has been committed to presenting the latest information on diabetes research, with special emphasis on type 1 and type 2 diabetes, islet biology, and high priority research areas identified by leading scientists, investigators, academic organizations, and industry. The symposium goal is to bring together leading and junior investigators and keep them abreast of the latest developments in diabetes research, creating opportunities for scientific interaction, collaborations, and debates. The symposium will also include oral presentations from trainees to allow for greater interaction with those more experienced in the field. Our aim is that this focused educational effort will continue to foster collaboration among established scientists, as well as further career development of trainees.

Target Audience

This educational program is directed towards endocrinologists, islet immunologists, islet biologists, stem cell scientists, diabetes complication and epigenetics scientists, clinical trialists, young and established trainees in all these areas and health care professionals from both the U.S. and abroad who manage patients with diabetes.

Learning Objectives

  • Demonstrate our understanding of the latest in beta cell biology.
  • Assess data on possible beta-alpha cross talk in functional and dysfunctional islets.
  • Examine the latest in islet development and role of microenvironment.
  • Analyze the latest advancement in pathophysiology of T2D.
  • Discuss genetic and epigenetics of diabetes and its complications.
  • Outline efficacy of cell therapy vs. standard of care in insulin deficient diabetes.
  • Review surgical vs. medical therapy of obesity and insulin resistance.
  • Discuss the new therapeutics and clinical trial results in T1 and T2 diabetes as well as in obesity.
  • Examine the latest information on liver steatosis and fibrosis as well as their therapeutics.
  • Analyze the current state of deriving stem cells into functional, hypoimmunogenic, clinical grade islet-like structures.
  • Review current state of islet encapsulation and extrahepatic sites of cell replacement therapies.
  • Discuss current state of beta cell proliferation in vivo: how, when and if at all clinically possible.
  • Demonstrate the understanding of cancer and diabetes interface.
  • Discuss possible barriers and biases which may impact patient care (i.e., race, ethnicity, language, gender identity/orientation, age, socioeconomic status, attitudes, feelings, or other characteristics).

Abstract Submission now open!
Abstract Submission Deadline: July 1, 2024 (by 11:59pm PT)
Abstract Committee Review: July 2 - July 9, 2024
Notification will be sent on July 10, 2024

Click here to access the Abstract Guidelines and link for submission.

ABSTRACT SUBMITTERS WILL BE NOTIFIED OF THE DECISIONS VIA EMAIL.

 

Join Us for the
2024 Rachmiel Levine-Arthur Riggs
Diabetes Research Symposium 
at The Westin Pasadena

Activity summary
Available credit: 
  • 18.25 AMA PRA Category 1 Credit™
    City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
    City of Hope designates this 2024 Rachmiel Levine-Arthur Riggs Diabetes Research Symposium for a maximum of 18.25 AMA PRA Category 1 Credit™ requirements. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 18.25 Attendance
Activity opens: 
02/06/2024
Activity expires: 
10/01/2024
Event starts: 
09/21/2024 - 7:00am PDT
Event ends: 
09/24/2024 - 1:45pm PDT
Cost:
$400.00

The Westin Pasadena
191 North Los Robles Ave.
Pasadena, CA 91101
United States

ROOM BLOCK 

A BLOCK OF ROOMS HAS BEEN RESERVED AT A SPECIAL CONFERENCE RATE FOR CONFIRMED REGISTERED ATTENDEES, AND WILL BE AVAILABLE ON A FIRST-COME, FIRST-SERVED BASIS.

Additional details coming soon!

Travel

Nearest Airports:

Hollywood Burbank Airport (Bob Hope)
Distance from Hotel: 16.1 miles/25.8 km
Drive Time: 22 minutes

Ontario International Airport
Distance From Hotel: 36.8 miles/59.3 km
Drive Time: 41 minutes

Los Angeles International Airport
Distance From Hotel: 28.3 miles/45.6 km
Drive Time: 56 minute

ACCREDITATION STATEMENT: City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION: City of Hope designates this live activity for a maximum of 18.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

The following credit type(s) are being offered for this course:

•  AMA PRA Category 1 Credit™  18.25

The following may apply AMA PRA Category 1 Credit™ for license renewal:

Registered Nurses: Nurses may report up to 18.25 credit hours toward the continuing education requirements for license renewal by their state Board of Registered Nurses (BRN). AMA PRA Category 1 Credit™ may be noted on the license renewal application in lieu of a BRN provider number.

Physician Assistants: The National Commission on Certification of Physicians Assistants states that AMA PRA Category 1 Credit™ accredited courses are acceptable for CME requirements for recertification.

DISCLOSURE INFORMATION: 

This activity has been planned and implemented in strict compliance with the accreditation requirements, standards, and policies of the ACCME. City of Hope takes responsibility for the content, quality and scientific integrity of this CME activity.

As an accredited CME provider City of Hope requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any ineligible company. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 24 months, that could create a conflict of interest, and an "ineligible company" as any entity producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. Any potential conflicts relative to the previous disclosure have been resolved.

Written disclosure of all such relevant financial relationships will be provided in the activity handout and/or syllabus. Any potential conflicts relative to the previous disclosure have been resolved.

City of Hope further encourages faculty/authors to identify investigational products or off-label uses of products regulated by the U.S. Food and Drug Administration, at first mention and where appropriate in the content.

The information and opinions presented in this activity do not constitute medical or legal advice. Health care providers must exercise their own professional judgment in their clinical practice, and when confronted with the issues discussed herein, should not substitute this curriculum for the advice of legal counsel or application of sound ethical principles.

Available Credit

  • 18.25 AMA PRA Category 1 Credit™
    City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
    City of Hope designates this 2024 Rachmiel Levine-Arthur Riggs Diabetes Research Symposium for a maximum of 18.25 AMA PRA Category 1 Credit™ requirements. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 18.25 Attendance

Exhibiting/Sponsorship at the 2024 Rachmiel Levine-Arthur Riggs Diabetes Research Symposium

City of Hope is pleased to offer the opportunity to exhibit and/or sponsor the 2024 Rachmiel Levine-Arthur Riggs Diabetes Research Symposium, an ACCME accredited symposium addressing diabetes.

Exhibit space & sponsorship is available to companies interested in participating in this symposium.

 

EXHIBITOR BOOTH/SPONSOR REGISTRATIONS CANNOT BE PROCESSED ONLINE.

Please contact the Department of Continuing Medical Education in order to receive more information, at csaavedra@coh.org.

Acknowledgment of Commercial Support: Any and all grant support will be acknowledged at the symposium via signage and will be listed in the symposium materials.

 

Price

Cost:
$400.00
Please login or register to take this activity.

You must be logged in to your account to complete your registration. 

Under "Registrant Type" dropdown (above), select your Registration Fee depending on your profession and click "Add to Cart". Follow the payment prompts. 

You will receive an email confirmation once you are registered.  

Registrant Type

*Early Bird Registration

(Before July 21, 2024)

Regular Registration

(After July 21, 2024)

Physician/Scientist$400$450
Fellow/Student /Nurse/Other Allied Health Care Provider$250$300
**Industry/Commercial Employee Attendee$700$750
Abstract Submission Fee$50N/A

Registration Fee: Registration fee includes all symposium sessions, CME Credit, symposium meals, refreshment breaks and reception

Cancellation Policy: Early Bird Registrations are nonrefundable. Refund requests must be submitted in writing and postmarked no later than Friday, August 9, 2024. A $50 processing fee will be applied for all refunds. Requests postmarked after DAY, DATE, will not be honored. All refunds will be processed 30 days after the meeting concludes. In the event of unforeseeable circumstances that lead to the cancellation by the symposium organizers, all registration fees will be fully refunded.

For questions, contact the Department of Continuing Medical Education at cme@coh.org or 626-218-5622 

*Early Bird Registrations are nonrefundable.
**Industry/Commercial Employee Attendee is defined as any individual employed by a for-profit, including biotech, financial and pharmaceutical.